Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for 2025. Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus ...

“Rapid molecular point-of-care testing can revolutionise ... said Matt Sause, CEO Roche Diagnostics.

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...

Roche has given two early-phase bispecifics ... The other axed Chugai candidate was SPYK04, a RAF-MEK molecular glue that the Japanese drugmaker removed (PDF) from its pipeline in October.

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based settings for patients at risk for chlamydia, gonorrhea, and Mycoplasma ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15-49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to ...

“Rapid molecular point-of-care testing can revolutionise the clinical ... and contain further spread by providing timely diagnosis.” said Matt Sause, CEO Roche Diagnostics.